Company attributes
Other attributes
ALX Oncology is a clinical-stage immuno-oncology company that focuses on helping patients combat cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
ALX Oncology was lauched by a team of industry professionals for addressing basic challenges in blocking CD47 and realizing the full potential of this therapeutic target.
ALX is developing a modern checkpoint inhibitor that is designed to have a high affinity for CD47 and avoid the limitations that are caused by hematologic toxicities inherent in other CD47 blocking approaches.
The company believes its lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on its clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, the company's strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.
